Entrada Therapeutics (TRDA) director-linked fund sells 116K shares
Rhea-AI Filing Summary
Entrada Therapeutics director and 10% owner Kush M. Parmar, through entities affiliated with 5AM Ventures, reported open-market sales totaling 116,474 shares of common stock on July 30–31, 2026 at per-share prices around 6.9300 and 6.8500. Shares are held by 5AM Ventures V, L.P. and 5AM Opportunities I, L.P., with Parmar disclaiming beneficial ownership beyond his pecuniary interest.
Positive
- None.
Negative
- None.
Insights
Analyzing...
Insider Trade Summary
Net Seller: 116,474 shares
Net Sell
3 txns
Insider
PARMAR KUSH
Role
Director, 10% Owner
Sold
116,474 shs ($807K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 1,718 | $6.85 | $12K |
| Sale | Common Stock F1, F2 | 114,756 | $6.93 | $795K |
| holding | Common Stock F3 | -- | -- | -- |
Holdings After Transaction:
Common Stock — 2,846,592 shares (Indirect, By 5AM Ventures V, L.P.);
Common Stock — 1,093,313 shares (Indirect, By 5AM Opportunities I, L.P.)
Footnotes (3)
- F1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.75 to $6.95 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F2. Shares are held by 5AM Ventures V, L.P. ("5AM V"). 5AM Partners V, LLC ("5AM Partners") is the sole general partner of 5AM V. Kush M. Parmar, M.D., Ph.D. is a managing member of 5AM Partners and may be deemed to share voting and investment power over the shares held by 5AM V. Dr. Parmar disclaims beneficial ownership of the shares held by 5AM V except to the extent of his pecuniary interest therein.
- F3. Shares are held by 5AM Opportunities I, L.P. ("Opportunities"). 5AM Opportunities I (GP), LLC ("Opportunities GP") is the sole general partner of Opportunities. Kush M. Parmar, M.D., Ph.D. is a managing member of Opportunities GP and may be deemed to share voting and investment power over the shares held by Opportunities. Dr. Parmar disclaims beneficial ownership of the shares held by Opportunities except to the extent of his pecuniary interest therein.
Key Figures
Shares sold 2026-07-30: 114756.0000 shares
Shares sold 2026-07-31: 1718.0000 shares
Total shares sold: 116474 shares
+2 more
5 metrics
Shares sold 2026-07-30
114756.0000 shares
Indirect sale of common stock by 5AM Ventures V, L.P. at 6.9300 per share
Shares sold 2026-07-31
1718.0000 shares
Additional indirect sale of common stock at 6.8500 per share
Total shares sold
116474 shares
Net shares sold across reported non-derivative transactions in this Form 4
Price range for 2026-07-30 sales
6.75 to 6.95 per share
Weighted average price footnote for 114756.0000 shares sold on 2026-07-30
Indirect holdings by 5AM Opportunities I, L.P.
1093313.0000 shares
Common stock position reported as held indirectly by 5AM Opportunities I, L.P.
Key Terms
weighted average price, beneficial ownership, pecuniary interest
3 terms
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
beneficial ownership financial
"Dr. Parmar disclaims beneficial ownership of the shares held by 5AM V except..."
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
pecuniary interest financial
"disclaims beneficial ownership of the shares... except to the extent of his pecuniary interest therein."
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider stock sales were reported for Entrada Therapeutics (TRDA)?
Entities linked to director Kush M. Parmar reported selling 116,474 shares of Entrada Therapeutics (TRDA) common stock. The sales occurred on July 30–31, 2026 at per-share prices of 6.9300 and 6.8500, according to the Form 4 filing.
Were the TRDA insider transactions tied to a Rule 10b5-1 trading plan?
The Form 4 indicates the document-level Rule 10b5-1 checkbox is not selected. The sales are described as open-market or private transactions, with no additional plan-related details provided in the transaction descriptions or footnotes.